How do we read adrenal evidence — the field whose folk concept has no diagnosis code?
Adrenal research splits into a rigorous core and a folklore periphery: the core — cortisol physiology, adrenal insufficiency management, steroid-taper science, Cushing's surgical outcomes — is endocrinology at its most precise, with timed assays and stimulation tests and mortality-hard endpoints. The periphery — 'adrenal fatigue,' glandulars, 'adrenal cocktails,' DHEA anti-aging — is the estate's clearest diagnosis-free zone: a popular concept with no consensus definition, no validated diagnostic criteria, and a product line built on the gap. This chapter reads the trials that exist (ashwagandha's HPA data, the C story, magnesium's stress studies), grades the nulls (DHEA), and retires the category the myth built.
The field with the sharpest diagnostic core and the loosest folk periphery teaches boundary literacy:
Bartolomeo Eustachius names the 'glandulae renibus incumbentes' — the glands resting on the kidneys. Their function stays a mystery for three centuries: anatomy without physiology.
Thomas Addison publishes his monograph on the disease that bears his name — the anemia, bronzing, and collapse of adrenal destruction. The first organ-specific endocrine disease described, and uniformly fatal until steroid replacement arrived eighty years later.
Hans Selye publishes the General Adaptation Syndrome — alarm, resistance, exhaustion — founding stress physiology. The first two stages stand confirmed; the third becomes the myth's word-shaped seed (Chapter 3's story).
Kendall and Hench's cortisone transforms rheumatoid arthritis overnight — Nobel-honored in 1950 — and opens both replacement therapy for Addison's and the iatrogenic suppression this page's taper rules exist for. The adrenal's greatest gift and its cautionary tale, one molecule.
The cholesterol-to-cortisol enzymatic cascade is elucidated — the pathway whose blocks become congenital adrenal hyperplasia, whose chemistry becomes the oral contraceptive's backbone, and whose vitamin-C-spending synthesis Chapter 3 teaches.
Modern replacement therapy makes Addison's a managed condition (with the crisis-prevention rules every patient carries); pheochromocytoma genetics and imaging sharpen the great mimic's capture; and the 'adrenal fatigue' concept grows from Selye's borrowed word into a supplement category — the folklore this page retires with the physiology it misread.
POPULATION · Chronically stressed adults across randomized trials of standardized ashwagandha extracts (300–600 mg daily, 8–12 weeks)
FINDING · Standardized root and root-leaf extracts reduced serum cortisol by roughly 20–30% versus placebo, with parallel improvements in perceived stress scores and sleep quality — the adaptogen class's best human dataset.
LIMITATION · Small-to-moderate samples, substantial industry affiliation (the extract licensees fund much of the base), and heterogeneous outcome instruments. Replicated directionality with honest caveats — the moderate grade this page assigns.
POPULATION · 64 chronically stressed adults, 300 mg vs 600 mg standardized extract vs placebo, 8 weeks
FINDING · Both doses reduced perceived stress and serum cortisol (600 mg more prominently) versus placebo — the dose-response data behind this page's 600 mg course framing.
LIMITATION · Single-center, industry-partnered (the extract's licensee), moderate sample — the trial that anchors the class and displays its ties simultaneously: read with the disclosure skill this chapter teaches.
POPULATION · Case series and pharmacovigilance reports of ashwagandha-associated hepatotoxicity
FINDING · Rare but repeatedly reported idiosyncratic liver injury with ashwagandha use — mostly cholestatic patterns, mostly resolving on discontinuation, occasionally severe.
LIMITATION · Case-report literature cannot establish incidence (the denominator problem); the signal is real enough for physician awareness and label cautions, rare enough to keep the moderate grade — the honest middle this library holds for its adaptogens.
POPULATION · Older adults (the DHEAge and related trials), 50 mg DHEA daily vs placebo, 1–2 years
FINDING · No meaningful benefit on body composition, strength, glucose, or quality-of-life measures versus placebo — the decline-correlation hypothesis meeting the RCT and losing.
LIMITATION · The nulls are as clean as anti-aging nulls get: adequate doses, durations, and endpoints. DHEA declines with age; supplementing it does not reverse aging — the correlation-fallacy teaching case.
POPULATION · Systematic reviews and endocrine-society position assessments of the 'adrenal fatigue' concept, its proposed tests, and its treatments
FINDING · No consensus definition, no validated diagnostic criteria, no consistent laboratory findings across studies — the concept fails as a diagnosis while succeeding as a marketing category.
LIMITATION · Absence of evidence is the finding: multiple systematic reviews have searched for the syndrome's definition and found none. The honest conclusion is not that tired people aren't tired — it is that this name, these tests, and these bottles are not the answer to their fatigue.